APRE
Aprea Therapeutics, Inc.·Healthcare
0.92
24.905%(+0.18)
Market ClosedLast Updated: — ET
52W L: $0.5552W H: $2.22
APRE NEWS
globenewswire.com
Apr 1
Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement
DOYLESTOWN, Pa., April 01, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced the closing of its previously announced oversubscribed private placement financing.
globenewswire.com
Mar 30
Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement
Financing led by Soleus Capital with participation from Vestal Point Capital, Squadron Capital Management and additional new and existing investors DOYLESTOWN, Pa., March 30, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced that it has entered into a securities purchase agreement for an oversubscribed private placement financing that is expected to result in total gross proceeds of approximately $30 million to the Company before deducting placement agent fees and other private placement expenses (the “Offering”).
globenewswire.com
Mar 30
Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial
Confirmed partial response at 220 mg indicates anti-tumor activity of APR-1051 in biomarker-defined cancers Early clinical data suggest the potential of APR-1051 as a best-in-class WEE1 inhibitor Emerging clinical proof of concept responses without class-limiting toxicity to date support Aprea's development strategy of differentiated WEE1 inhibition with an improved therapeutic index A further update from the trial is expected in the second quarter of 2026 DOYLESTOWN, Pa., March 30, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced the confirmation of a partial response (PR) in its ongoing ACESOT-1051 trial evaluating APR-1051, a potent and selective WEE1 kinase inhibitor.
defenseworld.net
Mar 17
Aprea Therapeutics (APRE) Projected to Post Quarterly Earnings on Tuesday
Aprea Therapeutics (NASDAQ: APRE - Get Free Report) will likely be releasing its Q4 2025 results before the market opens on Tuesday, March 24th. Analysts expect Aprea Therapeutics to post earnings of ($0.38) per share for the quarter. Parties can check the company's upcoming Q4 2025 earning summary page for the latest details on the call
globenewswire.com
Mar 16
Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
DOYLESTOWN, Pa., March 16, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.
benzinga.com
Feb 18
Aprea Therapeutics Advanced Cancer Trial Shows Promising Results, Stock Soars
Aprea Therapeutics (NASDAQ: APRE) shares are trading higher on Wednesday as the company announced additional preliminary data from its ongoing Phase 1 trial of APR-1051, a WEE1 kinase inhibitor.
